ClinicalTrials.Veeva

Menu

Prevalence of Primary Aldosteronism in Patients With Resistant Hypertension in China

S

Shanghai Jiao Tong University School of Medicine

Status

Completed

Conditions

Hypertension, Resistant to Conventional Therapy

Study type

Observational

Funder types

Other

Identifiers

NCT01459042
19830409

Details and patient eligibility

About

Recent studies indicate that primary aldosteronism (PA) is a much more common cause of hypertension than had been demonstrated historically. In patients with resistant hypertension, the prevalence of PA from different clinics worldwide is about 10-20%. As has been no such data in China, the investigators are conducting a PA study in different province of China to evaluate the prevalence of PA in patients with resistant hypertension.

Enrollment

2,000 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • patients with resistant hypertension
  • age 18-65 years

Exclusion criteria

  • known cause of hypertension
  • heart failure
  • renal dysfunction
  • Stroke, transient ischaemic attack or myocardial infarction in the past 6 months
  • cirrhosis
  • pregnancy
  • undertreatment of glucocorticoid

Trial design

2,000 participants in 2 patient groups

primary aldosteronism
essential hypertension

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems